Please try another search
Alzheon, Inc. develops small-molecule-based medicines for patients suffering from Alzheimer's and other neurological disorders. Its products include ALZ-801, an orally administered inhibitor of beta-amyloid misfolding that helps treat disease. The company's preclinical candidate compound includes ALZ-1903, a chemical entity and potent inhibitor of beta-amyloid misfolding. Alzheon, Inc. was incorporated in 2013 and is based in Framingham, Massachusetts.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review